Eloxx Pharmaceuticals, Inc.
ELOX · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $2 | $3 | $3 |
| G&A Expenses | $2 | $2 | $2 | $3 |
| SG&A Expenses | $2 | $2 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $4 | $5 | $6 |
| Operating Income | -$4 | -$4 | -$5 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$1 | -$0 |
| Pre-Tax Income | -$4 | -$4 | -$6 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$4 | -$6 | -$6 |
| % Margin | – | – | – | – |
| EPS | -1.31 | -1.96 | -2.88 | -2.92 |
| % Growth | 33.2% | 31.9% | 1.4% | – |
| EPS Diluted | -1.31 | -1.96 | -2.88 | -2.92 |
| Weighted Avg Shares Out | 3 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$4 | -$6 | -$6 |
| % Margin | – | – | – | – |